NASDAQ: INMBInmune Bio Inc Stock
$8.80+0.37 (+4.39%)
Updated Apr 18, 2024
INMB Price
$8.80
Fair Value Price
$1.30
Market Cap
$158.63M
52 Week Low
$6.50
52 Week High
$14.74
P/E
-5.27x
P/B
4.25x
P/S
1,306.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$155.00k
Earnings
-$30.01M
Gross Margin
100%
Operating Margin
-19,360%
Profit Margin
-19,360%
Debt to Equity
0.51
Operating Cash Flow
-$12M
Beta
1.02
Next Earnings
May 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A
INMB Overview
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INMB ($8.80) is overvalued by 575.41% relative to our estimate of its Fair Value price of $1.30 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INMB ($8.80) is not significantly undervalued (575.41%) relative to our estimate of its Fair Value price of $1.30 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INMB due diligence checks available for Premium users.
Be the first to know about important INMB news, forecast changes, insider trades & much more!
INMB News
Valuation
INMB fair value
Fair Value of INMB stock based on Discounted Cash Flow (DCF)
Price
$8.80
Fair Value
$1.30
Overvalued by
575.41%
INMB ($8.80) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INMB ($8.80) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INMB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.27x
Industry
15.68x
Market
41.33x
INMB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.25x
Industry
5.76x
INMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INMB's financial health
Profit margin
Revenue
$28.0k
Net Income
-$8.4M
Profit Margin
-30,028.6%
INMB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
INMB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$57.0M
Liabilities
$18.9M
Debt to equity
0.51
INMB's short-term assets ($39.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INMB's short-term assets ($39.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INMB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
INMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
$0.0
Financing
-$2.5M
INMB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INMB vs Biotech Stocks
Inmune Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.